Get started
Author

Kokoro Eshima

Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model
2018 · Kenzo Iizuka, Cheng Jin, et al. · Drug Design Development and Therapy · 14
PDF
Contribution of AP-1 Interference Induced by TAC-101 to Tumor Growth Suppression in a Hepatocellular Carcinoma Model
2009 · Kokoro Eshima, Satoshi Fukaya, et al. · Tumor Biology · 5
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo
2018 · Kenzo Iizuka, Chun Zhang, et al. · International Journal of Oncology · 3
PDF
Abstract 5099: Development of novel antimetabolite, DFP-11207, with self-toxicity protection and its promising preclinical and clinical profiles
2017 · Masakazu Fukushima, Kenzo Iizuka, et al. · Cancer Research
Abstract 2192: DFP-10825 IP delivery provides a new effective treatment option to peritoneal-disseminated cancers
2017 · Cheng Jin, Kenzo Iizuka, et al. · Cancer Research
Abstract B87: Preclinical investigation of the potentiation in antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, in combination with irinotecan (CPT-11) in colorectal cancer.
2013 · Keiji Ishida, Nozomu Tanaka, et al. · Molecular Cancer Therapeutics
Works count: 6
Citation count: 22
H-index: 3
I10-index: 1
Year
Topic
Type